Development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant (AMR) bacterial biothreat pathogens.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93022C00059
- Awardee
-
AN2 Therapeutics, Inc. UEI DD4FE2GE4L78
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,235,577
Award facts
- Opportunity
-
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases Pre-Solicitation · PHS20211 · Posted Feb 8, 2021
- Contract value 51% obligated
-
- $9,235,577.00 Current, with exercised options
- $18,274,778.00 Potential, with all options
- Completion date 85% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 30 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $456,766 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $3,821,365 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $651,041 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $4,306,405 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases awarded an $18.3 million definitive contract to AN2 Therapeutics, Inc. for development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial-resistant bacterial biothreat pathogens on September 20, 2022, with a completion date of July 31, 2027. The contract is priced on a cost, no fee basis.
The originating Broad Agency Announcement, posted February 8, 2021, solicited proposals across three research areas: advanced development of vaccine candidates, therapeutic product development, and sequencing-based diagnostics to further countermeasures against biothreat agents and antimicrobial-resistant infections. AN2 Therapeutics' award falls within the therapeutic development research area, which estimated total awards of up to $11 million. Place of performance is Menlo Park, CA.
Government-invoiced labor across the contract's performance shows scaling: FY2023 recorded $232 thousand (0.8 FTEs, 1,650 contractor hours) at $140.79/hr; FY2024 invoiced $2.3 million (2.2 FTEs, 4,576 contractor hours) at $500.18/hr; FY2025 invoiced $2.4 million (1.2 FTEs). The derived government-paid hourly rate rose year-over-year. FY2025 reflects prime self-performance with no reported subcontractors.
Quick answers
Who was awarded contract 75N93022C00059?
75N93022C00059 was awarded to AN2 Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 20, 2022.
How much is contract 75N93022C00059 worth?
The government has obligated $9,235,577 on 75N93022C00059. Its potential value, with all options, is $18,274,778.
Was contract 75N93022C00059 competed?
The extent of competition for 75N93022C00059 was full and open competition. The government received 30 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award